Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Senl 1904B (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Hebei Senlang Biotechnology

13 Dec 2022 Results of an analysis in patients treated with Chindamide maintenance therapy after CD-CAR-T therapy in this study and achieved CR on day 30 following CD19 CAR-T cells infusion and who were unable to bridge to allo-HSCT within 3 months presented at the 64th American Society of Hematology Annual Meeting and Exposition
13 Dec 2022 Status changed to completed, according to Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
16 Sep 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com